503Pharma Weekly Compounding Pharmacy Roundup

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

Lead Story

Retatrutide Posts Blockbuster Phase 3 Data — Raising the Stakes of the Classification Fight

Lilly's topline TRIUMPH-1 results, out today: at 80 weeks the 12 mg dose averaged 28.3% weight loss (70.3 lbs), with 45.3% of participants losing 30%+ — surgery-level results. Why we should care: the bigger retatrutide's commercial upside, the harder Lilly pushes to classify it as a biologic and lock compounders out, which is exactly what's being litigated in Lilly v. Kennedy below.

Eli Lilly → Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial

This Week's Headlines

Litigation

OFA Backs FDA in the Retatrutide “Biologic vs. Drug” Fight

Outsourcing Facilities Association (OFA) filed an amicus brief May 18 backing FDA in Lilly v. Kennedy (7th Cir., No. 26-1301), arguing biologic status would make retatrutide immune to compounding — the real prize alongside 12-year exclusivity.

LinkedIn → OFA amicus brief in Lilly v. Kennedy

Counterfeit Watch

Counterfeit Supply Moves In as Compounded Tirzepatide Tightens

CBP Philadelphia seized 32,000+ unapproved tablets smuggled from Europe. The second-order effect of closing legal pathways is plain: demand doesn't vanish, the black market absorbs it. Licensed pharmacies remain the safe source — worth repeating to patients.

CBP → Philadelphia officers seize over 32,000 unapproved and potentially dangerous medicines

Import Enforcement

House Subcommittee Advances Hazardous-Imports Bill

The House E&C Health Subcommittee advanced H.R. 2715, giving FDA authority to destroy refused-entry imports posing public-health risk. Why we should care: higher stakes on bulk API of uncertain provenance, especially foreign or “research use only” channels.

Congress.gov → H.R. 2715, Destruction of Hazardous Imports Act

Intel Briefs

GLP-1 Nuance

Liraglutide Is Still Fair Game

The April 30 proposal names all three GLP-1s together, but liraglutide injection is still on the shortage list — so 503Bs can compound it from bulk right now. Semaglutide and tirzepatide are closed.

Epstein Becker → FDA proposal would leave semaglutide, tirzepatide, and liraglutide off 503B bulks list

Peptide Timeline

GHK-Cu: Injectable vs. Non-Injectable

Treat the routes separately: the topical form was only ever in Category 1 (under evaluation, never safety-flagged), while the injectable sat in Category 2 (safety concerns). Both had nominations withdrawn, and neither is on the July PCAC agenda — FDA's review isn't until before the end of February 2027.

FDA → Bulk Drug Substances Nominated for Use in Compounding Under Section 503A

Research Desk

GLP-1 Indication Expansion

The GLP-1 Evidence Base Keeps Widening — Now Into Addiction and Cardiology

Four newly registered trials push these molecules well past weight loss. NIAAA began recruiting May 19 for a Phase 1b study of tirzepatide's dopaminergic effects in alcohol use disorder, using PET imaging; NIDA has a Phase 2 pilot of tirzepatide for cannabis use disorder. On the cardiovascular side, semaglutide is being studied before AF catheter ablation (SPICE-AF, Phase 4) and in acute ischemic stroke after thrombectomy (Phase 2). The throughline for compounders: demand for these molecules stays structurally high as indications multiply — even as the bulk pathways narrow.

ClinicalTrials.gov → Tirzepatide's Dopaminergic Effects in Alcohol Use Disorder

Compounded Hormones

New Studies on Estradiol, DHEA, and Testosterone

Three fresh registrations touch staples of the HRT formulary. University of Arizona is comparing vaginal estradiol cream vs. DHEA ovals in peri- and menopausal women (324 participants); a Danish group has a Phase 2 of testosterone in frail elderly men with deficiency; and Indiana University is testing slow-release DHEA — in asthma, not HRT, but a notable read on the molecule's delivery and safety. Worth watching as the evidence base for compounded hormone therapy builds.

ClinicalTrials.gov → Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women

CompoundLearn: Training Built for Compounding Pharmacies

CompoundLearn simplifies USP compliance training so your team can stay inspection-ready without the spreadsheets and paper trails. From onboarding new staff to competency testing, CompoundLearn automates the entire training lifecycle — so you can focus on what matters most: patient safety.

• Full access to 25 training modules and 77 lessons covering critical USP 795, 797, and 800 topics

• Role-based assignments — assign and track the right training curriculum to designated persons/pharmacists-in-charge, compounders, and trainers

• Quizzes and Downloadable certificates that prove that your team knows the material

• 23+ Ready-Made Compliance Templates — Downloadable cleaning logs, sampling records, labeling checklists, and more — ready to use out of the box

• Custom Module Creation — Build pharmacy-specific training for your unique protocols and SOPs

• Team & Role Management — Assign training by role (designated person, compounder, technician) and track progress across your entire organization

[Start Now at CompoundLearn →]

✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.